We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GSK (GSK) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
GSK (GSK - Free Report) closed at $38.32 in the latest trading session, marking a +1.62% move from the prior day. This change outpaced the S&P 500's 1.33% gain on the day. Meanwhile, the Dow gained 1.14%, and the Nasdaq, a tech-heavy index, added 2.94%.
Heading into today, shares of the drug developer had gained 12.3% over the past month, outpacing the Medical sector's gain of 7.14% and the S&P 500's gain of 6.11% in that time.
Wall Street will be looking for positivity from GSK as it approaches its next earnings report date. In that report, analysts expect GSK to post earnings of $0.85 per share. This would mark a year-over-year decline of 22.73%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $8.55 billion, down 34.8% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $3.50 per share and revenue of $35.81 billion. These totals would mark changes of +1.16% and -9.81%, respectively, from last year.
Any recent changes to analyst estimates for GSK should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. GSK is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, GSK is currently trading at a Forward P/E ratio of 10.77. This represents a discount compared to its industry's average Forward P/E of 21.37.
Meanwhile, GSK's PEG ratio is currently 1.91. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Biomedical and Genetics was holding an average PEG ratio of 2.01 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 73, putting it in the top 29% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GSK (GSK) Outpaces Stock Market Gains: What You Should Know
GSK (GSK - Free Report) closed at $38.32 in the latest trading session, marking a +1.62% move from the prior day. This change outpaced the S&P 500's 1.33% gain on the day. Meanwhile, the Dow gained 1.14%, and the Nasdaq, a tech-heavy index, added 2.94%.
Heading into today, shares of the drug developer had gained 12.3% over the past month, outpacing the Medical sector's gain of 7.14% and the S&P 500's gain of 6.11% in that time.
Wall Street will be looking for positivity from GSK as it approaches its next earnings report date. In that report, analysts expect GSK to post earnings of $0.85 per share. This would mark a year-over-year decline of 22.73%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $8.55 billion, down 34.8% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $3.50 per share and revenue of $35.81 billion. These totals would mark changes of +1.16% and -9.81%, respectively, from last year.
Any recent changes to analyst estimates for GSK should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. GSK is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, GSK is currently trading at a Forward P/E ratio of 10.77. This represents a discount compared to its industry's average Forward P/E of 21.37.
Meanwhile, GSK's PEG ratio is currently 1.91. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Biomedical and Genetics was holding an average PEG ratio of 2.01 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 73, putting it in the top 29% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.